Role of SCN5A coding and non-coding sequences in Brugada syndrome onset: What's behind the scenes?


Journal

Biomedical journal
ISSN: 2320-2890
Titre abrégé: Biomed J
Pays: United States
ID NLM: 101599820

Informations de publication

Date de publication:
08 2019
Historique:
received: 09 04 2018
revised: 20 02 2019
accepted: 11 03 2019
entrez: 20 10 2019
pubmed: 20 10 2019
medline: 15 4 2020
Statut: ppublish

Résumé

Brugada syndrome (BrS) is a rare inherited cardiac arrhythmia associated with a high risk of sudden cardiac death (SCD) due to ventricular fibrillation (VF). BrS is characterized by coved-type ST-segment elevation in the right precordial leads (V1-V3). Mutations in SCN5A gene coding for the α-subunit of the NaV1.5 cardiac sodium channel are identified in 15-30% of BrS cases. Genetic testing of BrS patients generally involves sequencing of the protein-coding portions and flanking intronic regions of SCN5A. This excludes the 5'UTR and 3'UTR from the routine genetic testing. We here screened the coding sequence, the flanking intronic regions as well as the 5' and 3'UTR regions of SCN5A gene and further five candidate genes (GPD1L, SCN1B, KCNE3, SCN4B, and MOG1) in a Tunisian family diagnosed with BrS. A new SCN5A-Q1000K mutation was identified along with two common polymorphisms (H558R and D1819). Multiple genetic variants were identified on the SCN5A 3'UTR, one of which is predicted to create additional microRNA binding site for miR-1270. Additionally, we identified the hsa-miR-219a-rs107822. No relevant coding sequence variant was identified in the remaining studied candidate genes. The absence of genotype-phenotype concordance within all the identified genetic variants in this family gives extra evidences about the complexity of the disease and suggests that the occurrence and prognosis of BrS is most likely controlled by a combination of multiple genetic factors, rather than a single variant. Most SCN5A variants were localized in non-coding regions hypothesizing an impact on the miRNA-target complementarities.

Sections du résumé

BACKGROUND
Brugada syndrome (BrS) is a rare inherited cardiac arrhythmia associated with a high risk of sudden cardiac death (SCD) due to ventricular fibrillation (VF). BrS is characterized by coved-type ST-segment elevation in the right precordial leads (V1-V3). Mutations in SCN5A gene coding for the α-subunit of the NaV1.5 cardiac sodium channel are identified in 15-30% of BrS cases. Genetic testing of BrS patients generally involves sequencing of the protein-coding portions and flanking intronic regions of SCN5A. This excludes the 5'UTR and 3'UTR from the routine genetic testing.
METHODS
We here screened the coding sequence, the flanking intronic regions as well as the 5' and 3'UTR regions of SCN5A gene and further five candidate genes (GPD1L, SCN1B, KCNE3, SCN4B, and MOG1) in a Tunisian family diagnosed with BrS.
RESULTS
A new SCN5A-Q1000K mutation was identified along with two common polymorphisms (H558R and D1819). Multiple genetic variants were identified on the SCN5A 3'UTR, one of which is predicted to create additional microRNA binding site for miR-1270. Additionally, we identified the hsa-miR-219a-rs107822. No relevant coding sequence variant was identified in the remaining studied candidate genes.
CONCLUSIONS
The absence of genotype-phenotype concordance within all the identified genetic variants in this family gives extra evidences about the complexity of the disease and suggests that the occurrence and prognosis of BrS is most likely controlled by a combination of multiple genetic factors, rather than a single variant. Most SCN5A variants were localized in non-coding regions hypothesizing an impact on the miRNA-target complementarities.

Identifiants

pubmed: 31627867
pii: S2319-4170(18)30167-7
doi: 10.1016/j.bj.2019.03.003
pmc: PMC6818142
pii:
doi:

Substances chimiques

MicroRNAs 0
NAV1.5 Voltage-Gated Sodium Channel 0
Potassium Channels, Voltage-Gated 0
SCN5A protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

252-260

Informations de copyright

Copyright © 2019 Chang Gung University. Published by Elsevier B.V. All rights reserved.

Références

Forensic Sci Int. 2017 Jun;275:187-194
pubmed: 28391114
Front Physiol. 2013 Jul 15;4:179
pubmed: 23874304
Circulation. 2006 Aug 1;114(5):368-76
pubmed: 16864729
Curr Opin Cardiol. 2010 May;25(3):210-5
pubmed: 20224390
Cell. 2007 Apr 20;129(2):303-17
pubmed: 17397913
Nucleic Acids Res. 2016 Sep 6;44(15):7120-31
pubmed: 27418678
Dis Markers. 2015;2015:541531
pubmed: 26379361
Cardiovasc Res. 2008 Sep 1;79(4):553-61
pubmed: 18539629
Heart Rhythm. 2015 Jun;12(6):1333-42
pubmed: 25701775
Circ Res. 2003 Oct 31;93(9):821-8
pubmed: 14500339
Circulation. 2002 Mar 19;105(11):1342-7
pubmed: 11901046
Gastroenterology. 2014 Jun;146(7):1659-1668
pubmed: 24613995
Breast Cancer Res Treat. 2013 Oct;141(3):447-59
pubmed: 24062209
Physiol Rep. 2015 Jan 27;3(1):null
pubmed: 25626866
J Clin Invest. 2003 Feb;111(3):341-6
pubmed: 12569159
Heart Rhythm. 2016 Apr;13(4):983-91
pubmed: 26711798
Circ Cardiovasc Genet. 2009 Dec;2(6):552-7
pubmed: 20031634
Circulation. 2013 Apr 2;127(13):1377-85
pubmed: 23463857
J Biol Chem. 2008 Mar 14;283(11):6968-78
pubmed: 18184654
Curr Probl Cardiol. 2005 Jan;30(1):9-54
pubmed: 15627121
Circulation. 2007 Jul 17;116(3):258-67
pubmed: 17606841
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2979-84
pubmed: 9501201
Heart. 2015 Jun;101(12):921-8
pubmed: 25814653
Science. 2007 Apr 27;316(5824):575-9
pubmed: 17379774
Physiol Genomics. 2003 Feb 06;12(3):187-93
pubmed: 12454206
Clin Pharmacol Ther. 2007 Jan;81(1):35-41
pubmed: 17185997
FEBS Open Bio. 2015 Aug 28;5:774-8
pubmed: 26609515
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Card Electrophysiol Clin. 2014 Dec 1;6(4):797-809
pubmed: 25395996
Methods Mol Biol. 2017;1617:27-37
pubmed: 28540674
Mol Genet Metab. 2002 Apr;75(4):317-24
pubmed: 12051963
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Pediatr Cardiol. 2015 Jun;36(5):1090-6
pubmed: 25758664
Heart Rhythm. 2004 Nov;1(5):600-7
pubmed: 15851227
Pacing Clin Electrophysiol. 2003 Jul;26(7 Pt 1):1551-3
pubmed: 12914638
Heart Rhythm. 2010 Jan;7(1):33-46
pubmed: 20129283
Circ Res. 2011 Apr 1;108(7):884-97
pubmed: 21454796

Auteurs

Houria Daimi (H)

Department of Experimental Biology, University of Jaen, Spain; Biochemistry and Molecular Biology Laboratory, Faculty of Pharmacy, University of Monastir, Monastir, Tunisia.

Amel Haj Khelil (AH)

Biochemistry and Molecular Biology Laboratory, Faculty of Pharmacy, University of Monastir, Monastir, Tunisia.

Ali Neji (A)

Fattouma Bourguiba Hospital, Monastir, Tunisia.

Khaldoun Ben Hamda (K)

Fattouma Bourguiba Hospital, Monastir, Tunisia.

Sabri Maaoui (S)

Fattouma Bourguiba Hospital, Monastir, Tunisia.

Amelia Aranega (A)

Department of Experimental Biology, University of Jaen, Spain.

Jemni Be Chibani (J)

Biochemistry and Molecular Biology Laboratory, Faculty of Pharmacy, University of Monastir, Monastir, Tunisia.

Diego Franco (D)

Department of Experimental Biology, University of Jaen, Spain. Electronic address: dfranco@ujaen.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH